US6475388B1
(en)
|
1996-11-13 |
2002-11-05 |
Transgenomic, Inc. |
Method and system for RNA analysis by matched ion polynucleotide chromatography
|
EP1800697B1
(en)
|
2001-06-05 |
2010-04-14 |
CureVac GmbH |
Stabilised mRNA with increased G/C-content for use in gene therapy
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
DE10229872A1
(en)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immune stimulation through chemically modified RNA
|
DE10335833A1
(en)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfection of blood cells with mRNA for immune stimulation and gene therapy
|
WO2005116204A1
(en)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
|
DE102004042546A1
(en)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
DE102005023170A1
(en)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimized formulation for mRNA
|
JP2009544754A
(en)
|
2006-07-28 |
2009-12-17 |
アプライド バイオシステムズ, エルエルシー |
Dinucleotide MRNA cap analog
|
DE102006035618A1
(en)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
|
EP2046954A2
(en)
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
DE102006061015A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Process for the purification of RNA on a preparative scale by HPLC
|
DE102007001370A1
(en)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-encoded antibodies
|
CA2692906C
(en)
|
2007-06-19 |
2016-01-19 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
EP2176408B9
(en)
|
2008-01-31 |
2015-11-11 |
Curevac GmbH |
NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
ES2470644T3
(en)
|
2008-05-26 |
2014-06-24 |
Universitt Zrich |
Protamine / RNA nanoparticles for immunostimulation
|
PL215513B1
(en)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
EP3225621A1
(en)
|
2008-10-09 |
2017-10-04 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
CA3039251C
(en)
|
2008-11-10 |
2024-01-09 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
CN102421417B
(en)
|
2009-05-05 |
2016-03-02 |
阿尔尼拉姆医药品有限公司 |
Lipid composition
|
EP2440183B1
(en)
|
2009-06-10 |
2018-07-18 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
JP5893611B2
(en)
|
2010-06-03 |
2016-03-23 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Biodegradable lipids for delivery of active agents
|
ES2558106T3
(en)
|
2010-07-30 |
2016-02-02 |
Curevac Ag |
Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
US8969545B2
(en)
|
2011-10-18 |
2015-03-03 |
Life Technologies Corporation |
Alkynyl-derivatized cap analogs, preparation and uses thereof
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
US9890391B2
(en)
|
2012-03-27 |
2018-02-13 |
Curevac Ag |
RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
|
CA2866945C
(en)
|
2012-03-27 |
2021-05-04 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
ES2654205T3
(en)
|
2012-03-27 |
2018-02-12 |
Curevac Ag |
Artificial nucleic acid molecules for enhanced protein or peptide expression
|
EP2854857B1
(en)
|
2012-05-25 |
2018-11-28 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
ES2702466T3
(en)
|
2013-08-21 |
2019-03-01 |
Curevac Ag |
Procedure to increase the expression of proteins encoded by RNA
|
CN105530952A
(en)
|
2013-08-21 |
2016-04-27 |
库瑞瓦格股份公司 |
Composition and vaccine for treating lung cancer
|
WO2015024669A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Combination vaccine
|
SG10201801431TA
(en)
|
2013-08-21 |
2018-04-27 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
BR112016000889A2
(en)
|
2013-08-21 |
2017-12-12 |
Curevac Ag |
composition and vaccine for prostate cancer treatment
|
CA2915712A1
(en)
|
2013-08-21 |
2015-02-26 |
Margit SCHNEE |
Rabies vaccine
|
ES2806575T3
(en)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
Modified RNA with decreased immunostimulatory properties
|
SG10201805660WA
(en)
|
2013-12-30 |
2018-08-30 |
Curevac Ag |
Methods for rna analysis
|
RU2717986C2
(en)
|
2013-12-30 |
2020-03-27 |
Куревак Аг |
Artificial molecules of nucleic acid
|
JP6584414B2
(en)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
Artificial nucleic acid molecule
|
ES2754239T3
(en)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
RU2595374C2
(en)
|
2014-04-09 |
2016-08-27 |
Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) |
Method for automated extraction with simultaneous purification of nucleic acids from several biological samples
|
PT3155129T
(en)
|
2014-06-10 |
2019-05-16 |
Curevac Ag |
Methods and means for enhancing rna production
|
DE202015009961U1
(en)
|
2014-12-12 |
2022-01-25 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein expression
|
CA2962849A1
(en)
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
SG11201704681QA
(en)
|
2014-12-30 |
2017-07-28 |
Curevac Ag |
Artificial nucleic acid molecules
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
CA2975333A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
EP3289101B1
(en)
|
2015-04-30 |
2021-06-23 |
CureVac AG |
Immobilized poly(n)polymerase
|
CN108064307A
(en)
|
2015-04-30 |
2018-05-22 |
库瑞瓦格股份公司 |
The method for carrying out in-vitro transcription using the restriction enzyme of immobilization
|
EP3294885B1
(en)
|
2015-05-08 |
2020-07-01 |
CureVac Real Estate GmbH |
Method for producing rna
|
EP3294326B1
(en)
|
2015-05-15 |
2021-04-21 |
CureVac AG |
Prime-boost regimens involving administration of at least one mrna construct
|
EP3298142B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
SG11201708541QA
(en)
|
2015-05-20 |
2017-12-28 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
DK3303583T3
(en)
|
2015-05-29 |
2020-07-13 |
Curevac Real Estate Gmbh |
METHOD FOR PREPARATION AND PURIFICATION OF RNA, INCLUDING AT LEAST ONE STEP FOR TANGENTIAL FLOW FILTRATION
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
WO2017001058A1
(en)
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
US20200085852A1
(en)
|
2015-08-05 |
2020-03-19 |
Curevac Ag |
Epidermal mrna vaccine
|
EP3332019B1
(en)
|
2015-08-07 |
2019-12-18 |
CureVac AG |
Process for the in vivo production of rna in a host cell
|
DE22195354T1
(en)
|
2015-08-10 |
2023-05-25 |
CureVac Manufacturing GmbH |
METHOD OF INCREASING REPLICATION OF A CIRCULAR DNA MOLECULE
|
BR112018001995A2
(en)
|
2015-08-28 |
2018-09-18 |
Curevac Ag |
artificial nucleic acid molecules
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
AU2016340183A1
(en)
|
2015-10-16 |
2018-04-19 |
Modernatx, Inc. |
mRNA cap analogs and methods of mRNA capping
|
SI3362461T1
(en)
|
2015-10-16 |
2022-05-31 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
US20180312545A1
(en)
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
EP3394237A1
(en)
|
2015-12-21 |
2018-10-31 |
CureVac AG |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
WO2017109134A1
(en)
|
2015-12-22 |
2017-06-29 |
Curevac Ag |
Method for producing rna molecule compositions
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
EP3414340B1
(en)
|
2016-02-12 |
2023-08-09 |
CureVac SE |
Method for analyzing rna
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
SG10201913630YA
(en)
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
US20190177714A1
(en)
|
2016-03-24 |
2019-06-13 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
WO2017182634A1
(en)
|
2016-04-22 |
2017-10-26 |
Curevac Ag |
Rna encoding a tumor antigen
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
WO2017203008A1
(en)
|
2016-05-25 |
2017-11-30 |
Curevac Ag |
Novel biomarkers
|
EP3468608A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
US20190336608A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
US11478552B2
(en)
|
2016-06-09 |
2022-10-25 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
CN106442827B
(en)
*
|
2016-07-18 |
2018-01-19 |
北京工业大学 |
It is a kind of using fluid dynamic chromatogram simultaneously the multigroup microRNA of separation detection method
|
CN109715205A
(en)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
RNA use for cancer treatment
|
CN110352071A
(en)
|
2016-10-26 |
2019-10-18 |
库瑞瓦格股份公司 |
Lipidic nanoparticles mRNA vaccine
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
EP3808380A1
(en)
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
EP3595715A1
(en)
|
2017-03-17 |
2020-01-22 |
CureVac AG |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
EP3601576A1
(en)
|
2017-03-24 |
2020-02-05 |
CureVac AG |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
US20230064106A1
(en)
|
2017-05-17 |
2023-03-02 |
Curevac Real Estate Gmbh |
Method for determining at least one quality parameter of an rna sample
|
EP3648791A1
(en)
|
2017-07-04 |
2020-05-13 |
CureVac AG |
Novel nucleic acid molecules
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
KR20200071081A
(en)
|
2017-10-19 |
2020-06-18 |
큐어백 아게 |
New artificial nucleic acid molecule
|
RU2020117848A
(en)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
PHK SEQUENCE ADAPTATION
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
JP2021519595A
(en)
|
2018-04-17 |
2021-08-12 |
キュアバック アーゲー |
New RSV RNA molecule and vaccination composition
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
MX2020013148A
(en)
|
2018-06-28 |
2021-03-02 |
CureVac RNA Printer GmbH |
Bioreactor for rna in vitro transcription.
|
TW202039534A
(en)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
Kras variant mrna molecules
|
CA3122645A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
CA3125511A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
BR112022001947A2
(en)
|
2019-08-14 |
2022-09-20 |
Curevac Ag |
RNA COMBINATIONS AND COMPOSITIONS WITH REDUCED IMMUNOSTIMULATORY PROPERTIES
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
KR20230053008A
(en)
|
2020-05-29 |
2023-04-20 |
큐어백 에스이 |
Nucleic Acid-Based Combination Vaccines
|